Blockbuster Oncology Brands Market Size, Share & Trends Analysis Report By Brand (Opdivo, Revlimid, Zejula), By Indication (Lung Cancer, Lymphoma, Multiple Myeloma), And Segment Forecasts, 2018 - 2027
This report can be delivered to the clients within 24 Business Hours
The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, according to a new report by Grand View Research, Inc., progressing at a CAGR of 7.3% during the forecast period. Shift towards immunotherapies coupled with increasing number of indication expansion trials is one of the primary growth stimulants for the market.
Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo’s sales, while Revlimid’s patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immunotherapeutic is expected to trail behind the latter by 2027.
Lifecycle management strategies, including expansion of approved indications and development of combination therapies, underline competitive dynamics in the global blockbuster oncology brands market. Collaborative agreements signed by participating companies facilitate development, commercialization, and regional expansion of products. Such strategies not only enable players to gain easy access into new markets, but also allow them to leverage scientific and technological expertise of their collaborative partner.
Further key findings from the report suggest:
The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, according to a new report by Grand View Research, Inc., progressing at a CAGR of 7.3% during the forecast period. Shift towards immunotherapies coupled with increasing number of indication expansion trials is one of the primary growth stimulants for the market.
Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo’s sales, while Revlimid’s patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immunotherapeutic is expected to trail behind the latter by 2027.
Lifecycle management strategies, including expansion of approved indications and development of combination therapies, underline competitive dynamics in the global blockbuster oncology brands market. Collaborative agreements signed by participating companies facilitate development, commercialization, and regional expansion of products. Such strategies not only enable players to gain easy access into new markets, but also allow them to leverage scientific and technological expertise of their collaborative partner.
Further key findings from the report suggest:
- North America dominated the global arena in 2017, with approximately 65.0% share. The region is likely to maintain its position through 2027
- In terms of revenue, the lung cancer segment is estimated to expand at a CAGR of over 9.0% during the forecast period
- The multiple myeloma segment held more than 30.0% of the market revenue in 2017 and is anticipated to lose its position to lung cancer by 2027
- Europe is projected to experience modest growth during the forecast period due to delays in cost-effectiveness analysis, carried out by health technology assessment bodies, slowing approval process and lowering reimbursement
- Some of the key companies present in the market are Tesaro, Inc.; Merck &Co.; Bristol Myers Squibb; AstraZeneca Plc; and Roche Ltd.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Research Methodology
1.2 Research Scope And Assumptions
1.3 List Of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation
CHAPTER 4 MARKET DEFINITIONS
CHAPTER 5 INDUSTRY OUTLOOK
5.1 Business Segment Trend Analysis
5.2 Pricing Analysis
5.3 Market Variable Analysis
5.3.1 Market Drivers Analysis
5.3.1.1 Accelerated Approvals Expedite Market Launch
5.3.1.2 Immuno-Oncology Therapies As First Line Treatment
5.3.2 Market Restraints Analysis
5.3.2.1 High Therapy Costs Hinders Market Access
5.4 Business Environment Analysis Tools
5.4.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological)
5.4.2 Porter’s Five Forces Analysis
CHAPTER 6 COMPETITIVE & VENDOR LANSCAPE
6.1 Market Participation Categorization
6.1.1 Market Leaders
6.1.2 Innovators
6.2 Strategic Initiatives & Outcome Analysis
6.2.1 List Of Key Strategies, By Company
6.4 List Of Key Companies, By Region
6.5 List Of Key Companies, By Indication
6.6 List Of Key Companies, By Brands
6.7 Company Market Share Analysis
CHAPTER 7 REGULATORY AND POLITICAL FORCES
7.1 Regulatory Landscape
7.1.1 North America
7.1.2 Europe
7.1.3 Asia Pacific
7.1.4 Middle East & Africa
7.1.5 Latin America
CHAPTER 8 BRANDS BUSINESS ANALYSIS
8.1 Blockbuster Oncology Brands Market: Brand Analysis
8.1.1. Tagrisso
8.1.1.1 Tagrisso, By Revenue, 2015 - 2027 (USD Million)
8.1.2 Tecentriq
8.1.2.1 Tecentriq, By Revenue, 2015 - 2027 (USD Million)
8.1.3 Ibrance
8.1.3.1 Ibrance, By Revenue, 2015 - 2027 (USD Million)
8.1.4 Perjeta
8.1.4.1 Perjeta, By Revenue, 2015 - 2027 (USD Million)
8.1.5 Zejula
8.1.5.1 Zejula, By Revenue, 2015 - 2027 (USD Million)
8.1.6 Gazyva
8.1.6.1 Gazyva, By Revenue, 2015 - 2027 (USD Million)
8.1.7 Revlimid
8.1.7.1 Revlimid, By Revenue, 2015 - 2027 (USD Million)
8.1.8 Darzalex
8.1.8.1 Darzalex, By Revenue, 2015 - 2027 (USD Million)
8.1.9 Imbruvica
8.1.9.1 Imbruvica, By Revenue, 2015 - 2027 (USD Million)
8.1.10 Opdivo
8.1.10.1 Opdivo, By Revenue, 2015 - 2027 (USD Million)
8.1.11 Keytruda
8.1.11.1 Keytruda, By Revenue, 2015 - 2027 (USD Million)
CHAPTER 9 INDICATIONS BUSINESS ANALYSIS
9.1. Blockbuster Oncolgoy Brands: Indications Movement Analysis
9.1.1. Lung Cancer
9.1.1.1 Lung Cancer Estimates And Forecasts, 2015 - 2027 (USD Million)
9.1.2 Breast Cancer
9.1.2.1 Breast Cancer Estimates And Forecasts, 2015 - 2027 (USD Million)
9.1.3 Multiple Myeloma
9.1.3.1 Multiple Myeloma Estimates And Forecasts, 2015 - 2027 (USD Million)
9.1.4 Lymphoma
9.1.4.1 Lymphoma Estimates And Forecasts, 2015 - 2027 (USD Million)
9.1.5 Others
9.1.5.1 Lymphoma Estimates And Forecasts, 2015 - 2027 (USD Million)
CHAPTER 10 REGIONAL BUSINESS ANALYSIS
10.1. Blockbuster Oncology Brands Market: Regional Movement Analysis
10.1.1. North America
10.1.1.1 North America Market Estimates And Forecast, 2015 - 2027
10.1.1.2 U.S.
10.1.1.2.1 U.S. Blockbuster Oncology Brands Market, 2015 - 2027 (USD Million)
10.1.1.3 Canada
10.1.1.3.1 Canada Blockbuster Oncology Brands Market, 2015 - 2027 (USD Million)
10.1.2. Europe
10.1.2.1 Europe Market Estimates And Forecast, 2015 - 2027
10.1.2.2 Germany
10.1.2.2.1 Germany Market Estimates And Forecast, 2015 - 2027
10.1.2.3 U.K.
10.1.2.3.1 U.K. Market Estimates And Forecast, 2015 - 2027
10.1.2.4 France
10.1.2.4.1 France Market Estimates And Forecast, 2015 - 2027
10.1.2.5 Italy
10.1.2.5.1 Italy Market Estimates And Forecast, 2015 - 2027
10.1.2.6 Spain
10.1.2.6.1 Spain Market Estimates And Forecast, 2015 - 2027
10.1.2.7 Denmark
10.1.2.7.1 Denmark Market Estimates And Forecast, 2015 - 2027
10.1.2.8 Switzerland
10.1.2.8.1 Switzerland Market Estimates And Forecast, 2015 - 2027
10.1.2.9 Poland
10.1.2.9.1 Poland Market Estimates And Forecast, 2015 - 2027
10.1.3 Asia Pacific
10.1.3.1 Asia Pacific Market Estimates And Forecast, 2015 - 2027
10.1.3.2 Japan
10.1.3.2.1 Japan Market Estimates And Forecast, 2015 - 2027
10.1.3.3 China.
10.1.3.3.1 China Market Estimates And Forecast, 2015 - 2027
10.1.3.4 India
10.1.3.4.1 India Market Estimates And Forecast, 2015 - 2027
10.1.3.5 New Zealand
10.1.3.5.1 New Zealand Market Estimates And Forecast, 2015 - 2027
10.1.3.6 Australia
10.1.3.6.1 Australia Market Estimates And Forecast, 2015 - 2027
10.1.3.7 Philippines
10.1.3.7.1 Philippines Market Estimates And Forecast, 2015 - 2027
10.1.3.8 S.Korea
10.1.3.8.1 S.Korea Market Estimates And Forecast, 2015 - 2027
10.1.3.9 Indonesia
10.1.3.9.1 Indonesia Market Estimates And Forecast, 2015 - 2027
10.1.3.10 Hong Kong
10.1.3.10.1 Hong Kong Market Estimates And Forecast, 2015 - 2027
10.1.3.11 Singapore
10.1.3.11.1 Singapore Market Estimates And Forecast, 2015 - 2027
10.1.4 Latin America
10.1.4.1 Latin America Market Estimates And Forecast, 2015 - 2027
10.1.4.2 Brazil
10.1.4.2.1 Brazil Market Estimates And Forecast, 2015 - 2027
10.1.4.3 Mexico
10.1.4.3.1 Mexico Market Estimates And Forecast, 2015 - 2027
10.1.4.4 Argentina
10.1.4.4.1 Argentina Market Estimates And Forecast, 2015 - 2027
10.1.5 Middle-East
10.1.5.1 Middle-East And Africa Market Estimates And Forecast, 2015 - 2027
10.1.5.2 Saudi Arabia
10.1.5.2.1 Saudi Arabia Market Estimates And Forecast, 2015 - 2027
10.1.5.3 Turkey.
10.1.5.3.1 Turkey Market Estimates And Forecast, 2015 - 2027
10.1.5.4 Israel
10.1.5.4.1 Israel Market Estimates And Forecast, 2015 - 2027
CHAPTER 11 COMPANY PROFILE
11.1 BRISTOL MYERS SQUIBB
11.1.1 Company overview
11.1.2 Financial performance
11.1.3 Product overview
11.1.4 Regulatory developments
11.1.5 Product pipeline
11.1.6 Business strategies
11.1.7 Swot analysis
11.2 MERCK & CO.
11.2.1 Company overview
11.2.2 Financial performance
11.2.3 Product overview
11.2.4 Regulatory developments
11.2.5 Product pipeline
11.2.6 Business strategies
11.2.7 Swot analysis
11.3 ROCHE
11.3.1 Company overview
11.3.2 Financial performance
11.3.3 Product overview
11.3.4 Product pipeline
11.3.5 Business strategies
11.3.6 Swot analysis
11.4 PFIZER
11.4.1 Company overview
11.4.2 Financial performance
11.4.3 Product overview
11.4.4 Product pipeline
11.4.5 Business strategies
11.4.6 Swot analysis
11.5 ASTRAZENECA
11.5.1 Company overview
11.5.2 Financial performance
11.5.3 Product overview
11.5.4 Product pipeline
11.5.5 Business strategies
11.5.6 swot analysis
11.6 TESARO
11.6.1 Company overview
11.6.2 Financial performance
11.6.3 Product overview
11.6.4 Product pipeline
11.6.5 Business strategies
11.6.6 Swot analysis
CHAPTER 12 PIPELINE ANALYSIS
12.1 Therapies in focus
12.2 Strong future players
12.3 Market outlook
1.1 Research Methodology
1.2 Research Scope And Assumptions
1.3 List Of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation
CHAPTER 4 MARKET DEFINITIONS
CHAPTER 5 INDUSTRY OUTLOOK
5.1 Business Segment Trend Analysis
5.2 Pricing Analysis
5.3 Market Variable Analysis
5.3.1 Market Drivers Analysis
5.3.1.1 Accelerated Approvals Expedite Market Launch
5.3.1.2 Immuno-Oncology Therapies As First Line Treatment
5.3.2 Market Restraints Analysis
5.3.2.1 High Therapy Costs Hinders Market Access
5.4 Business Environment Analysis Tools
5.4.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological)
5.4.2 Porter’s Five Forces Analysis
CHAPTER 6 COMPETITIVE & VENDOR LANSCAPE
6.1 Market Participation Categorization
6.1.1 Market Leaders
6.1.2 Innovators
6.2 Strategic Initiatives & Outcome Analysis
6.2.1 List Of Key Strategies, By Company
6.4 List Of Key Companies, By Region
6.5 List Of Key Companies, By Indication
6.6 List Of Key Companies, By Brands
6.7 Company Market Share Analysis
CHAPTER 7 REGULATORY AND POLITICAL FORCES
7.1 Regulatory Landscape
7.1.1 North America
7.1.2 Europe
7.1.3 Asia Pacific
7.1.4 Middle East & Africa
7.1.5 Latin America
CHAPTER 8 BRANDS BUSINESS ANALYSIS
8.1 Blockbuster Oncology Brands Market: Brand Analysis
8.1.1. Tagrisso
8.1.1.1 Tagrisso, By Revenue, 2015 - 2027 (USD Million)
8.1.2 Tecentriq
8.1.2.1 Tecentriq, By Revenue, 2015 - 2027 (USD Million)
8.1.3 Ibrance
8.1.3.1 Ibrance, By Revenue, 2015 - 2027 (USD Million)
8.1.4 Perjeta
8.1.4.1 Perjeta, By Revenue, 2015 - 2027 (USD Million)
8.1.5 Zejula
8.1.5.1 Zejula, By Revenue, 2015 - 2027 (USD Million)
8.1.6 Gazyva
8.1.6.1 Gazyva, By Revenue, 2015 - 2027 (USD Million)
8.1.7 Revlimid
8.1.7.1 Revlimid, By Revenue, 2015 - 2027 (USD Million)
8.1.8 Darzalex
8.1.8.1 Darzalex, By Revenue, 2015 - 2027 (USD Million)
8.1.9 Imbruvica
8.1.9.1 Imbruvica, By Revenue, 2015 - 2027 (USD Million)
8.1.10 Opdivo
8.1.10.1 Opdivo, By Revenue, 2015 - 2027 (USD Million)
8.1.11 Keytruda
8.1.11.1 Keytruda, By Revenue, 2015 - 2027 (USD Million)
CHAPTER 9 INDICATIONS BUSINESS ANALYSIS
9.1. Blockbuster Oncolgoy Brands: Indications Movement Analysis
9.1.1. Lung Cancer
9.1.1.1 Lung Cancer Estimates And Forecasts, 2015 - 2027 (USD Million)
9.1.2 Breast Cancer
9.1.2.1 Breast Cancer Estimates And Forecasts, 2015 - 2027 (USD Million)
9.1.3 Multiple Myeloma
9.1.3.1 Multiple Myeloma Estimates And Forecasts, 2015 - 2027 (USD Million)
9.1.4 Lymphoma
9.1.4.1 Lymphoma Estimates And Forecasts, 2015 - 2027 (USD Million)
9.1.5 Others
9.1.5.1 Lymphoma Estimates And Forecasts, 2015 - 2027 (USD Million)
CHAPTER 10 REGIONAL BUSINESS ANALYSIS
10.1. Blockbuster Oncology Brands Market: Regional Movement Analysis
10.1.1. North America
10.1.1.1 North America Market Estimates And Forecast, 2015 - 2027
10.1.1.2 U.S.
10.1.1.2.1 U.S. Blockbuster Oncology Brands Market, 2015 - 2027 (USD Million)
10.1.1.3 Canada
10.1.1.3.1 Canada Blockbuster Oncology Brands Market, 2015 - 2027 (USD Million)
10.1.2. Europe
10.1.2.1 Europe Market Estimates And Forecast, 2015 - 2027
10.1.2.2 Germany
10.1.2.2.1 Germany Market Estimates And Forecast, 2015 - 2027
10.1.2.3 U.K.
10.1.2.3.1 U.K. Market Estimates And Forecast, 2015 - 2027
10.1.2.4 France
10.1.2.4.1 France Market Estimates And Forecast, 2015 - 2027
10.1.2.5 Italy
10.1.2.5.1 Italy Market Estimates And Forecast, 2015 - 2027
10.1.2.6 Spain
10.1.2.6.1 Spain Market Estimates And Forecast, 2015 - 2027
10.1.2.7 Denmark
10.1.2.7.1 Denmark Market Estimates And Forecast, 2015 - 2027
10.1.2.8 Switzerland
10.1.2.8.1 Switzerland Market Estimates And Forecast, 2015 - 2027
10.1.2.9 Poland
10.1.2.9.1 Poland Market Estimates And Forecast, 2015 - 2027
10.1.3 Asia Pacific
10.1.3.1 Asia Pacific Market Estimates And Forecast, 2015 - 2027
10.1.3.2 Japan
10.1.3.2.1 Japan Market Estimates And Forecast, 2015 - 2027
10.1.3.3 China.
10.1.3.3.1 China Market Estimates And Forecast, 2015 - 2027
10.1.3.4 India
10.1.3.4.1 India Market Estimates And Forecast, 2015 - 2027
10.1.3.5 New Zealand
10.1.3.5.1 New Zealand Market Estimates And Forecast, 2015 - 2027
10.1.3.6 Australia
10.1.3.6.1 Australia Market Estimates And Forecast, 2015 - 2027
10.1.3.7 Philippines
10.1.3.7.1 Philippines Market Estimates And Forecast, 2015 - 2027
10.1.3.8 S.Korea
10.1.3.8.1 S.Korea Market Estimates And Forecast, 2015 - 2027
10.1.3.9 Indonesia
10.1.3.9.1 Indonesia Market Estimates And Forecast, 2015 - 2027
10.1.3.10 Hong Kong
10.1.3.10.1 Hong Kong Market Estimates And Forecast, 2015 - 2027
10.1.3.11 Singapore
10.1.3.11.1 Singapore Market Estimates And Forecast, 2015 - 2027
10.1.4 Latin America
10.1.4.1 Latin America Market Estimates And Forecast, 2015 - 2027
10.1.4.2 Brazil
10.1.4.2.1 Brazil Market Estimates And Forecast, 2015 - 2027
10.1.4.3 Mexico
10.1.4.3.1 Mexico Market Estimates And Forecast, 2015 - 2027
10.1.4.4 Argentina
10.1.4.4.1 Argentina Market Estimates And Forecast, 2015 - 2027
10.1.5 Middle-East
10.1.5.1 Middle-East And Africa Market Estimates And Forecast, 2015 - 2027
10.1.5.2 Saudi Arabia
10.1.5.2.1 Saudi Arabia Market Estimates And Forecast, 2015 - 2027
10.1.5.3 Turkey.
10.1.5.3.1 Turkey Market Estimates And Forecast, 2015 - 2027
10.1.5.4 Israel
10.1.5.4.1 Israel Market Estimates And Forecast, 2015 - 2027
CHAPTER 11 COMPANY PROFILE
11.1 BRISTOL MYERS SQUIBB
11.1.1 Company overview
11.1.2 Financial performance
11.1.3 Product overview
11.1.4 Regulatory developments
11.1.5 Product pipeline
11.1.6 Business strategies
11.1.7 Swot analysis
11.2 MERCK & CO.
11.2.1 Company overview
11.2.2 Financial performance
11.2.3 Product overview
11.2.4 Regulatory developments
11.2.5 Product pipeline
11.2.6 Business strategies
11.2.7 Swot analysis
11.3 ROCHE
11.3.1 Company overview
11.3.2 Financial performance
11.3.3 Product overview
11.3.4 Product pipeline
11.3.5 Business strategies
11.3.6 Swot analysis
11.4 PFIZER
11.4.1 Company overview
11.4.2 Financial performance
11.4.3 Product overview
11.4.4 Product pipeline
11.4.5 Business strategies
11.4.6 Swot analysis
11.5 ASTRAZENECA
11.5.1 Company overview
11.5.2 Financial performance
11.5.3 Product overview
11.5.4 Product pipeline
11.5.5 Business strategies
11.5.6 swot analysis
11.6 TESARO
11.6.1 Company overview
11.6.2 Financial performance
11.6.3 Product overview
11.6.4 Product pipeline
11.6.5 Business strategies
11.6.6 Swot analysis
CHAPTER 12 PIPELINE ANALYSIS
12.1 Therapies in focus
12.2 Strong future players
12.3 Market outlook
LIST OF TABLES
Table 1 Global Blockbuster Oncology Brands Market, by region, 2015 - 2027 (USD Million)
Table 2 Global Blockbuster Oncology Brands Market, by Indications, 2015 - 2027 (USD Million)
Table 3 Global Blockbuster Oncology Brands Market, by Brands, 2015 - 2027 (USD Million)
Table 4 North America Market, by country, 2015 - 2027 (USD Million)
Table 5 North America Market, by Indication, 2015 - 2027 (USD Million)
Table 6 North America Market, by Brand, 2015 - 2027 (USD Million)
Table 7 U.S. Market, by Indication, 2015 - 2027 (USD Million)
Table 8 U.S. Market, by Brand, 2015 - 2027 (USD Million)
Table 9 Canada Market, by Indication, 2015 - 2027 (USD Million)
Table 10 Canada Market, by Brand, 2015 - 2027 (USD Million)
Table 11 Europe Market, by country, 2015 - 2027 (USD Million)
Table 12 Europe Market, by Indication, 2015 - 2027 (USD Million)
Table 13 Europe Market, by Brands, 2015 - 2027 (USD Million)
Table 14 France Market, by Brands, 2015 - 2027 (USD Million)
Table 15 France Market, by Indication, 2015 - 2027 (USD Million)
Table 16 Germany Market, by Indication, 2015 - 2027 (USD Million)
Table 17 Germany Market, by Brands, 2015 - 2027 (USD Million)
Table 18 Italy Market, by Indication, 2015 - 2027 (USD Million)
Table 19 Italy Market, by Brands, 2015 - 2027 (USD Million)
Table 20 Spain Market, by Indication, 2015 - 2027 (USD Million)
Table 21 Spain Market, by Brands, 2015 - 2027 (USD Million)
Table 22 UK Market, by Indication, 2015 - 2027 (USD Million)
Table 23 UK Market, by Brands, 2015 - 2027 (USD Million)
Table 24 Switzerland Market, by Indication, 2015 - 2027 (USD Million)
Table 25 Switzerland Market, by Brands, 2015 - 2027 (USD Million)
Table 26 Denmark Market, by Indication, 2015 - 2027 (USD Million)
Table 27 Denmark Market, by Brands, 2015 - 2027 (USD Million)
Table 28 Poland Market, by Indication, 2015 - 2027 (USD Million)
Table 29 Poland Market, by Brands, 2015 - 2027 (USD Million)
Table 30 APAC Market, by country, 2015 - 2027 (USD Million)
Table 31 APAC Market, by Indication, 2015 - 2027 (USD Million)
Table 32 APAC Market, by Brands, 2015 - 2027 (USD Million)
Table 33 Hong Kong Market, by Indication, 2015 - 2027 (USD Million)
Table 34 Hong Kong Market, by Brand, 2015 - 2027 (USD Million)
Table 35 Singapore Market, by Indication, 2015 - 2027 (USD Million)
Table 36 Singapore Market, by Brands, 2015 - 2027 (USD Million)
Table 37 China Market, by Indication, 2015 - 2027 (USD Million)
Table 38 China Market, by Brands, 2015 - 2027 (USD Million)
Table 39 India Market, by Indication, 2015 - 2027 (USD Million)
Table 40 India Market, by Brands, 2015 - 2027 (USD Million)
Table 41 Japan Market, by Indication, 2015 - 2027 (USD Million)
Table 42 Japan Market, by Brands, 2015 - 2027 (USD Million)
Table 43 Indonesia Market, by Indication, 2015 - 2027 (USD Million)
Table 44 Indonesia Market, by Brands, 2015 - 2027 (USD Million)
Table 45 New Zealand Market, by Indication, 2015 - 2027 (USD Million)
Table 46 New Zealand Market, by Brands, 2015 - 2027 (USD Million)
Table 47 Australia Market, by Indication, 2015 - 2027 (USD Million)
Table 48 Australia Market, by Brands, 2015 - 2027 (USD Million)
Table 49 Philippines Market, by Indication, 2015 - 2027 (USD Million)
Table 50 Philippines Market, by Brands, 2015 - 2027 (USD Million)
Table 51 South Korea Market, by Indication, 2015 - 2027 (USD Million)
Table 52 South Korea Market, by Brands, 2015 - 2027 (USD Million))
Table 53 Latin America Market, by country, 2015 - 2027 (USD Million)
Table 54 Latin America Market, by Indication, 2015 - 2027 (USD Million)
Table 55 Latin America Market, by Brands, 2015 - 2027 (USD Million)
Table 56 Argentina Market, by Brands, 2015 - 2027 (USD Million)
Table 57 Argentina Market, by Indication, 2015 - 2027 (USD Million)
Table 58 Brazil Market, by Indication, 2015 - 2027 (USD Million)
Table 59 Brazil Market, by Brands, 2015 - 2027 (USD Million)
Table 60 Mexico Market, by Indication, 2015 - 2027 (USD Million)
Table 61 Mexico Market, by Brands, 2015 - 2027 (USD Million)
Table 62 MEA Market, by country, 2015 - 2027 (USD Million)
Table 63 MEA Market, by Indication, 2015 - 2027 (USD Million)
Table 64 MEA Market, by Brands, 2015 - 2027 (USD Million)
Table 65 Saudi Arabia Market, by Indication, 2015 - 2027 (USD Million)
Table 66 Saudi Arabia Market, by Brands, 2015 - 2027 (USD Million)
Table 67 Turkey Market, by Indication, 2015 - 2027 (USD Million)
Table 68 Turkey Market, by Brands, 2015 - 2027 (USD Million)
Table 69 Israel Market, by Brands, 2015 - 2027 (USD Million)
Table 70 Israel Market, by Brands, 2015 - 2027 (USD Million)
Table 1 Global Blockbuster Oncology Brands Market, by region, 2015 - 2027 (USD Million)
Table 2 Global Blockbuster Oncology Brands Market, by Indications, 2015 - 2027 (USD Million)
Table 3 Global Blockbuster Oncology Brands Market, by Brands, 2015 - 2027 (USD Million)
Table 4 North America Market, by country, 2015 - 2027 (USD Million)
Table 5 North America Market, by Indication, 2015 - 2027 (USD Million)
Table 6 North America Market, by Brand, 2015 - 2027 (USD Million)
Table 7 U.S. Market, by Indication, 2015 - 2027 (USD Million)
Table 8 U.S. Market, by Brand, 2015 - 2027 (USD Million)
Table 9 Canada Market, by Indication, 2015 - 2027 (USD Million)
Table 10 Canada Market, by Brand, 2015 - 2027 (USD Million)
Table 11 Europe Market, by country, 2015 - 2027 (USD Million)
Table 12 Europe Market, by Indication, 2015 - 2027 (USD Million)
Table 13 Europe Market, by Brands, 2015 - 2027 (USD Million)
Table 14 France Market, by Brands, 2015 - 2027 (USD Million)
Table 15 France Market, by Indication, 2015 - 2027 (USD Million)
Table 16 Germany Market, by Indication, 2015 - 2027 (USD Million)
Table 17 Germany Market, by Brands, 2015 - 2027 (USD Million)
Table 18 Italy Market, by Indication, 2015 - 2027 (USD Million)
Table 19 Italy Market, by Brands, 2015 - 2027 (USD Million)
Table 20 Spain Market, by Indication, 2015 - 2027 (USD Million)
Table 21 Spain Market, by Brands, 2015 - 2027 (USD Million)
Table 22 UK Market, by Indication, 2015 - 2027 (USD Million)
Table 23 UK Market, by Brands, 2015 - 2027 (USD Million)
Table 24 Switzerland Market, by Indication, 2015 - 2027 (USD Million)
Table 25 Switzerland Market, by Brands, 2015 - 2027 (USD Million)
Table 26 Denmark Market, by Indication, 2015 - 2027 (USD Million)
Table 27 Denmark Market, by Brands, 2015 - 2027 (USD Million)
Table 28 Poland Market, by Indication, 2015 - 2027 (USD Million)
Table 29 Poland Market, by Brands, 2015 - 2027 (USD Million)
Table 30 APAC Market, by country, 2015 - 2027 (USD Million)
Table 31 APAC Market, by Indication, 2015 - 2027 (USD Million)
Table 32 APAC Market, by Brands, 2015 - 2027 (USD Million)
Table 33 Hong Kong Market, by Indication, 2015 - 2027 (USD Million)
Table 34 Hong Kong Market, by Brand, 2015 - 2027 (USD Million)
Table 35 Singapore Market, by Indication, 2015 - 2027 (USD Million)
Table 36 Singapore Market, by Brands, 2015 - 2027 (USD Million)
Table 37 China Market, by Indication, 2015 - 2027 (USD Million)
Table 38 China Market, by Brands, 2015 - 2027 (USD Million)
Table 39 India Market, by Indication, 2015 - 2027 (USD Million)
Table 40 India Market, by Brands, 2015 - 2027 (USD Million)
Table 41 Japan Market, by Indication, 2015 - 2027 (USD Million)
Table 42 Japan Market, by Brands, 2015 - 2027 (USD Million)
Table 43 Indonesia Market, by Indication, 2015 - 2027 (USD Million)
Table 44 Indonesia Market, by Brands, 2015 - 2027 (USD Million)
Table 45 New Zealand Market, by Indication, 2015 - 2027 (USD Million)
Table 46 New Zealand Market, by Brands, 2015 - 2027 (USD Million)
Table 47 Australia Market, by Indication, 2015 - 2027 (USD Million)
Table 48 Australia Market, by Brands, 2015 - 2027 (USD Million)
Table 49 Philippines Market, by Indication, 2015 - 2027 (USD Million)
Table 50 Philippines Market, by Brands, 2015 - 2027 (USD Million)
Table 51 South Korea Market, by Indication, 2015 - 2027 (USD Million)
Table 52 South Korea Market, by Brands, 2015 - 2027 (USD Million))
Table 53 Latin America Market, by country, 2015 - 2027 (USD Million)
Table 54 Latin America Market, by Indication, 2015 - 2027 (USD Million)
Table 55 Latin America Market, by Brands, 2015 - 2027 (USD Million)
Table 56 Argentina Market, by Brands, 2015 - 2027 (USD Million)
Table 57 Argentina Market, by Indication, 2015 - 2027 (USD Million)
Table 58 Brazil Market, by Indication, 2015 - 2027 (USD Million)
Table 59 Brazil Market, by Brands, 2015 - 2027 (USD Million)
Table 60 Mexico Market, by Indication, 2015 - 2027 (USD Million)
Table 61 Mexico Market, by Brands, 2015 - 2027 (USD Million)
Table 62 MEA Market, by country, 2015 - 2027 (USD Million)
Table 63 MEA Market, by Indication, 2015 - 2027 (USD Million)
Table 64 MEA Market, by Brands, 2015 - 2027 (USD Million)
Table 65 Saudi Arabia Market, by Indication, 2015 - 2027 (USD Million)
Table 66 Saudi Arabia Market, by Brands, 2015 - 2027 (USD Million)
Table 67 Turkey Market, by Indication, 2015 - 2027 (USD Million)
Table 68 Turkey Market, by Brands, 2015 - 2027 (USD Million)
Table 69 Israel Market, by Brands, 2015 - 2027 (USD Million)
Table 70 Israel Market, by Brands, 2015 - 2027 (USD Million)
LIST OF FIGURES
Fig. 1 Blockbuster oncology brands market snapshot
Fig. 2 Blockbuster Oncology brands market segmentation
Fig. 3 Blockbuster oncology brands market driver impact
Fig. 4 Blockbuster oncology brands market restraintr impact
Fig. 5 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 6 Porter’s Five Forces Analysis
Fig. 7 Value Chain Analysis
Fig. 8 Blockbuster oncology brands market:brands outlook and key takeaways
Fig. 9 Blockbuster oncology brands Market: Brands Movement Analysis
Fig. 10 Tagrisso, 2015 - 2027 (USD Million)
Fig. 11 Tecentriq, 2015 - 2027 (USD Million)
Fig. 12 Tecentriq, 2015 - 2027 (USD Million)
Fig. 13 Tecentriq, 2015 - 2027 (USD Million)
Fig. 14 Zejula, 2015 - 2027 (USD Million)
Fig. 15 Gazyva, 2015 - 2027 (USD Million)
Fig. 16 Revlimid, 2015 - 2027 (USD Million)
Fig. 17 Darzalex, 2015 - 2027 (USD Million)
Fig. 18 Imbruvica, 2015 - 2027 (USD Million)
Fig. 19 Opdivo, 2015 - 2027 (USD Million)
Fig. 20 Keytruda, 2015 - 2027 (USD Million)
Fig. 21 Blockbuster oncology brands market indication outlook and key takeaways
Fig. 22 Blockbuster oncology brands Market: Indication Movement Analysis
Fig. 23 Lung cancer , 2015 - 2027 (USD Million)
Fig. 24 Breast cancer market, 2015 - 2027 (USD Million)
Fig. 25 Multiple myeloma market, 2015 - 2027 (USD Million)
Fig. 26 lymphoma market, 2015 - 2027 (USD Million)
Fig. 27 Blockbuster oncology brandsmarket: regional outlook and key takeaways
Fig. 28 CTMS Market: Regional Movement Analysis
Fig. 29 North America
Fig. 30 North America market estimates and forecast, 2015 - 2027
Fig. 31 U.S. Blockbuster Oncology Brands market, 2015 - 2027 (USD Million)
Fig. 32 Canada Blockbuster Oncology Brands market, 2015 - 2027 (USD Million)
Fig. 33 Europe
Fig. 34 Europe market estimates and forecast, 2015 - 2027
Fig. 35 Germany market estimates and forecast, 2015 - 2027
Fig. 36 U.K. market estimates and forecast, 2015 - 2027
Fig. 37 France market estimates and forecast, 2015 - 2027
Fig. 38 Italy market estimates and forecast, 2015 - 2027
Fig. 39 Spain market estimates and forecast, 2015 - 2027
Fig. 40 Denmark market estimates and forecast, 2015 - 2027
Fig. 41 Switzerland market estimates and forecast, 2015 - 2027
Fig. 42 Poland. market estimates and forecast, 2015 - 2027
Fig. 43 Asia-Pacific
Fig. 44 Asia-Pacific market estimates and forecast, 2015 - 2027
Fig. 45 Japan market estimates and forecast, 2015 - 2027
Fig. 46 China. market estimates and forecast, 2015 - 2027
Fig. 47 India market estimates and forecast, 2015 - 2027
Fig. 48 Thailand market estimates and forecast, 2015 - 2027
Fig. 49 Australia market estimates and forecast, 2015 - 2027
Fig. 50 Philippines market estimates and forecast, 2015 - 2027
Fig. 51 South Korea market estimates and forecast, 2015 - 2027
Fig. 52 Indonesia. market estimates and forecast, 2015 - 2027
Fig. 53 Hong Kong market estimates and forecast, 2015 - 2027
Fig. 54 Singapore. market estimates and forecast, 2015 - 2027
Fig. 55 Latin America
Fig. 56 Latin America market estimates and forecast, 2015 - 2027
Fig. 57 Brazil market estimates and forecast, 2015 - 2027
Fig. 58 Mexico market estimates and forecast, 2015 - 2027
Fig. 59 Argentina market estimates and forecast, 2015 - 2027
Fig. 60 Middle East & Africa
Fig. 61 Middle east market estimates and forecast, 2015 - 2027
Fig. 62 Suadi Arabia market estimates and forecast, 2015 - 2027
Fig. 63 Turkey market estimates and forecast, 2015 - 2027
Fig. 64 Israel market estimates and forecast, 2015 - 2027
Fig. 65 Company Profile
Fig. 1 Blockbuster oncology brands market snapshot
Fig. 2 Blockbuster Oncology brands market segmentation
Fig. 3 Blockbuster oncology brands market driver impact
Fig. 4 Blockbuster oncology brands market restraintr impact
Fig. 5 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 6 Porter’s Five Forces Analysis
Fig. 7 Value Chain Analysis
Fig. 8 Blockbuster oncology brands market:brands outlook and key takeaways
Fig. 9 Blockbuster oncology brands Market: Brands Movement Analysis
Fig. 10 Tagrisso, 2015 - 2027 (USD Million)
Fig. 11 Tecentriq, 2015 - 2027 (USD Million)
Fig. 12 Tecentriq, 2015 - 2027 (USD Million)
Fig. 13 Tecentriq, 2015 - 2027 (USD Million)
Fig. 14 Zejula, 2015 - 2027 (USD Million)
Fig. 15 Gazyva, 2015 - 2027 (USD Million)
Fig. 16 Revlimid, 2015 - 2027 (USD Million)
Fig. 17 Darzalex, 2015 - 2027 (USD Million)
Fig. 18 Imbruvica, 2015 - 2027 (USD Million)
Fig. 19 Opdivo, 2015 - 2027 (USD Million)
Fig. 20 Keytruda, 2015 - 2027 (USD Million)
Fig. 21 Blockbuster oncology brands market indication outlook and key takeaways
Fig. 22 Blockbuster oncology brands Market: Indication Movement Analysis
Fig. 23 Lung cancer , 2015 - 2027 (USD Million)
Fig. 24 Breast cancer market, 2015 - 2027 (USD Million)
Fig. 25 Multiple myeloma market, 2015 - 2027 (USD Million)
Fig. 26 lymphoma market, 2015 - 2027 (USD Million)
Fig. 27 Blockbuster oncology brandsmarket: regional outlook and key takeaways
Fig. 28 CTMS Market: Regional Movement Analysis
Fig. 29 North America
Fig. 30 North America market estimates and forecast, 2015 - 2027
Fig. 31 U.S. Blockbuster Oncology Brands market, 2015 - 2027 (USD Million)
Fig. 32 Canada Blockbuster Oncology Brands market, 2015 - 2027 (USD Million)
Fig. 33 Europe
Fig. 34 Europe market estimates and forecast, 2015 - 2027
Fig. 35 Germany market estimates and forecast, 2015 - 2027
Fig. 36 U.K. market estimates and forecast, 2015 - 2027
Fig. 37 France market estimates and forecast, 2015 - 2027
Fig. 38 Italy market estimates and forecast, 2015 - 2027
Fig. 39 Spain market estimates and forecast, 2015 - 2027
Fig. 40 Denmark market estimates and forecast, 2015 - 2027
Fig. 41 Switzerland market estimates and forecast, 2015 - 2027
Fig. 42 Poland. market estimates and forecast, 2015 - 2027
Fig. 43 Asia-Pacific
Fig. 44 Asia-Pacific market estimates and forecast, 2015 - 2027
Fig. 45 Japan market estimates and forecast, 2015 - 2027
Fig. 46 China. market estimates and forecast, 2015 - 2027
Fig. 47 India market estimates and forecast, 2015 - 2027
Fig. 48 Thailand market estimates and forecast, 2015 - 2027
Fig. 49 Australia market estimates and forecast, 2015 - 2027
Fig. 50 Philippines market estimates and forecast, 2015 - 2027
Fig. 51 South Korea market estimates and forecast, 2015 - 2027
Fig. 52 Indonesia. market estimates and forecast, 2015 - 2027
Fig. 53 Hong Kong market estimates and forecast, 2015 - 2027
Fig. 54 Singapore. market estimates and forecast, 2015 - 2027
Fig. 55 Latin America
Fig. 56 Latin America market estimates and forecast, 2015 - 2027
Fig. 57 Brazil market estimates and forecast, 2015 - 2027
Fig. 58 Mexico market estimates and forecast, 2015 - 2027
Fig. 59 Argentina market estimates and forecast, 2015 - 2027
Fig. 60 Middle East & Africa
Fig. 61 Middle east market estimates and forecast, 2015 - 2027
Fig. 62 Suadi Arabia market estimates and forecast, 2015 - 2027
Fig. 63 Turkey market estimates and forecast, 2015 - 2027
Fig. 64 Israel market estimates and forecast, 2015 - 2027
Fig. 65 Company Profile
